Equities

Dynavax Technologies Corp

Dynavax Technologies Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.41
  • Today's Change0.045 / 0.36%
  • Shares traded319.01k
  • 1 Year change-7.97%
  • Beta1.3292
Data delayed at least 15 minutes, as of Nov 22 2024 18:38 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

  • Revenue in USD (TTM)260.81m
  • Net income in USD20.48m
  • Incorporated2000
  • Employees408.00
  • Location
    Dynavax Technologies Corp2100 Powell Street, Suite 720EMERYVILLE 94608United StatesUSA
  • Phone+1 (510) 848-5100
  • Fax+1 (510) 848-1327
  • Websitehttps://www.dynavax.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Intellia Therapeutics Inc43.09m-522.28m1.40bn526.00--1.46--32.53-5.45-5.450.45099.460.0357--5.6281,912.55-43.22-31.34-47.07-34.53-----1,212.19-654.71----0.00---30.403.57-1.48--17.08--
Cassava Sciences Inc0.00-17.66m1.54bn29.00--9.26-----0.3772-0.37720.003.470.00----0.00-8.91-30.74-10.98-32.12------------0.00-------27.50------
Neumora Therapeutics Inc0.00-293.70m1.55bn108.00--4.85-----1.77-1.770.002.000.00----0.00-65.46---70.23--------------0.00-------80.23------
BioCryst Pharmaceuticals Inc412.58m-123.82m1.55bn536.00------3.76-0.6073-0.60732.01-2.260.81360.42976.54769,736.90-24.42-47.95-32.17-64.8998.0697.06-30.01-114.942.73-0.4882.29--22.3774.218.33--42.73--
Viridian Therapeutics Inc302.00k-257.08m1.55bn96.00--3.00--5,146.21-4.31-4.310.0058.940.0006--5.213,212.77-46.71-55.59-49.63-60.32-----85,127.15-5,678.12----0.0282---82.28-48.16-83.05--15.08--
Travere Therapeutics Inc203.45m-348.96m1.57bn380.00------7.69-4.52-4.562.63-0.39090.30430.719210.24535,386.80-52.19-36.95-69.25-44.7795.2195.92-171.52-165.791.68--1.09--32.69-2.43-13.54--16.49--
Nurix Therapeutics Inc56.42m-176.98m1.58bn284.00--3.98--28.08-2.91-2.910.92225.620.1373----198,676.10-43.07-33.01-52.51-39.66-----313.65-260.65----0.00--99.3115.5020.19--39.42--
Dynavax Technologies Corp260.81m20.48m1.62bn408.00101.252.3864.906.230.12210.12211.835.190.25630.804.36639,242.602.014.162.145.7182.8564.837.859.1912.34--0.2470.00-67.8695.19-102.18---23.03--
Recursion Pharmaceuticals Inc65.18m-377.75m1.65bn500.00--3.13--25.29-1.53-1.530.26311.830.096--24.06130,368.00-55.66---65.45--35.07---579.51------0.0519--11.88---36.99------
Xencor Inc85.16m-198.24m1.69bn280.00--2.33--19.80-3.20-3.201.3710.350.0967--2.61304,157.20-22.89-3.70-24.90-4.12-----236.81-15.92----0.0243--2.2832.90-128.50--18.36--
Structure Therapeutics Inc (ADR)0.00-110.55m1.72bn148.00--1.92-----2.21-2.210.0015.660.00----0.00-19.23---20.17--------------0.00-------69.62------
Arvinas Inc161.10m-308.60m1.73bn445.00--2.94--10.71-4.79-4.792.388.530.1448--14.01362,022.50-27.73-22.01-37.81-26.47-----191.56-316.55----0.001---40.2640.53-30.02--0.4852--
Celldex Therapeutics, Inc.9.98m-154.08m1.74bn160.00--2.21--174.37-2.57-2.570.16411.850.0181--18.0762,350.00-27.93-29.65-29.53-31.42-----1,544.48-1,747.94----0.00--192.02-6.32-25.91--17.46--
Fortrea Holdings Inc2.77bn-233.60m1.75bn15.50k--1.16--0.6297-2.62-3.4031.0916.870.6954--3.20154,155.60-5.85---7.29--18.49---8.42-----0.61410.4263--0.4167---101.76------
Data as of Nov 22 2024. Currency figures normalised to Dynavax Technologies Corp's reporting currency: US Dollar USD

Institutional shareholders

63.73%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 202419.31m14.69%
Deep Track Capital LPas of 22 Oct 202417.79m13.53%
The Vanguard Group, Inc.as of 30 Sep 20248.89m6.77%
Kynam Capital Management LPas of 30 Sep 20248.33m6.34%
SSgA Funds Management, Inc.as of 30 Sep 20247.69m5.85%
Federated Global Investment Management Corp.as of 30 Sep 20245.60m4.26%
Chicago Capital LLCas of 30 Sep 20245.49m4.18%
Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 20243.99m3.03%
Dimensional Fund Advisors LPas of 30 Sep 20243.68m2.80%
Geode Capital Management LLCas of 30 Sep 20243.00m2.28%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.